TA systems |
|
|
|
|
|
abkA/abkB
|
-Imipenem (10 × MIC)
-Imipenem combined with chlorhexidine (0.25 × MIC)
|
References ATCC 19606,
&17978 + clinical isolate Ab-2_clon_2010-CHLX
|
|
×
|
[53]
|
RelB/RelE |
|
|
× |
|
[45], [46],
[61] |
HigBAb/HigAAb |
-Ceftazidime (50
× MIC) |
Reference ATCC 19606 |
× |
|
[113] |
hicA/hicB |
-Ciprofloxacin (50 × MIC) |
Reference ATCC 17978 |
× |
|
[63] |
PPK |
-Ampicillin (40 × MIC) |
Reference ATCC 17978 |
× |
|
[68] |
Secondary messenger |
|
|
|
|
|
(p)ppGpp relA
|
-Colistin (50 × MIC)
-Rifampin (80 × MIC)
|
Clinical isolate 5075
+ its mutant ΔrelA
|
|
×
|
[80]
|
SOS response
|
-Ciprofloxacin (50 × MIC)
-Ciprofloxacin (10 mg/L)
-Imipenem (10 mg/L)
|
Reference ATCC 17978
Reference ATCC 19606 + two clinical strains
|
×
×
|
|
[63]
[105]
|
ROS
|
-Amikacin (2 × MIC)
-Carbenicillin (5 × MIC)
|
clinical isolate M22
|
×
|
|
[111]
|
Membrane changes
|
-Ciprofloxacin (100 × MIC)
-Meropenem (15 × MIC)
-Meropenem
(100 × MIC + 10 × MIC)
|
Reference ATCC 19606T
Clinical isolate Acb-1
Clinical isolate AYE
|
×
×
|
×
|
[123]
[124]
[125]
|
PAA operon |
-Ceftazidime (50 × MIC) |
Reference ATCC 19606 |
× |
|
[113] |